Viatris reported 2025 revenue of $14.30 billion and Q1 2026 revenue of $3.52 billion. The thesis depends on durable generic-drug cash flow, portfolio pruning, debt reduction, regulatory execution and proof that recent losses are not masking a weakening franchise.
The valuation workbench is hidden from non-admin users until market-data licensing and trust disclosures are production-ready.
